10% Owner Converts $20.16M Preferred Stock to Common Ahead of Merger

summarizeSummary

A 10% owner converted $20.16 million in preferred stock to common shares at $4.03 per share, positioning a large block of shares for the company's pending acquisition by Ligand Pharmaceuticals.

check_boxKey Events

• Significant Conversion by 10% Owner

  Mark N. Lampert and associated entities, a 10% owner, converted Series X Convertible Preferred Stock into 5,003,000 shares of common stock.

• Substantial Transaction Value

  The conversion represents a total value of $20,162,090, executed at a conversion price of $4.03 per share.

• Pre-Merger Positioning

  This conversion occurs ahead of XOMA Royalty Corp's acquisition by Ligand Pharmaceuticals for $39.00 per share, allowing the preferred shareholder to participate in the merger.

auto_awesomeAnalysis

Mark N. Lampert and affiliated entities, a 10% owner, converted a substantial amount of preferred stock into common shares. This action, valued at over $20 million, is a significant step for the major shareholder to prepare their holdings for the upcoming acquisition of XOMA Royalty Corp by Ligand Pharmaceuticals at $39.00 per share. While a conversion rather than an open-market purchase, its large scale makes it an important pre-merger transaction.